Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Repligen is buying BioLife Solutions in a $1.5 billion deal to expand its cell therapy product portfolio that biopharma companies rely on for manufacturing.
Repligen
Repligen is a bioprocessing-focused life sciences company developing and commercializing highly innovative bioprocessing technologies that are flexible, scalable, and cost-effective. Recently struck a $1.5 billion deal to acquire BioLife Solutions to expand its cell therapy product portfolio.
Company Info
Upcoming Milestones & Key Dates
Q4 2026
M&A
BioLife acquisition close
Clinical Development Pipeline
Cell therapy manufacturing products
Target: MultipleGene therapy manufacturing products
Target: MultipleBioprocessing resins and ligands
Target: MultipleRecent News
Leadership Team
Tony J. Hunt
President and Chief Executive Officer
To be confirmed
Chief Financial Officer
To be confirmed
Chief Operating Officer